Financial Results Announcement - ImmuCell Corporation announced preliminary, unaudited product sales for the year ended December 31, 2024[6]. - The press release detailing the financial results was issued on January 9, 2025[6]. - The report does not include specific financial figures or performance metrics in the provided content[6]. - The financial statements and exhibits related to the report are included as an attachment[8]. Company Information - The company is listed on The NASDAQ Capital Market under the trading symbol ICCC[4]. - The company has not indicated whether it is an emerging growth company[5]. - The report was signed by Michael F. Brigham, the President and CEO of ImmuCell Corporation[12]. Product and Market Development - No new product or technology developments were mentioned in the available content[6]. - There are no details regarding market expansion or acquisitions in the provided information[6]. Regulatory Compliance - The filing is intended to satisfy the requirements of the Securities Exchange Act of 1934[7].
ImmuCell(ICCC) - 2024 Q4 - Annual Results